Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maintenance therapy for patients with relapsed Multiple Myeloma

Next Previous
X
Search
Trial Profile

A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maintenance therapy for patients with relapsed Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Blood mononuclear cell therapy; Ciprofloxacin; Dexamethasone; Low molecular weight heparins; Melphalan; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms ReLApsE

    • Most Recent Events

    • 12 Dec 2023 Results assessing long term follow up results from the GMMG ReLApsE trial, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 04 Dec 2018 Primary endpoint has not been met. (Progression-free survival:), as reported in an abstract presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top